On June 26, 2024, VivoSense participated in the 7th annual Digital Biomarkers in Clinical Trials Summit in Basel, Switzerland. At the conference, leaders in digital health provided case studies that demonstrated the value of incorporating real-world digital endpoints in clinical trials across therapeutic areas.
At the Summit, Senior Research Scientist Shelby Bachman, PhD, introduced a longitudinal, multimodal study that VivoSense is currently conducting in individuals living with cancer. This study has two major aims: (1) to assess the feasibility and acceptability of remote monitoring using wrist-worn devices in this population and (2) to investigate how measures of real-world physical behavior, captured with wearable sensors, are related to established measures of physical function in oncology.
In her presentation, Shelby provided an overview of the study’s design, including how we are taking a multimodal approach to measuring physical function and our approach to returning results to participants in the study. In addition, she presented lessons learned since launching the study. In particular, preliminary results from the study have indicated that cancer treatment, as well as device features such as battery life, can impact participants’ willingness to wear a device on their wrist. Going forward, identifying factors that impact wear compliance in individuals living with cancer will be important for understanding the clinical utility of digital measures of real-world physical behavior in oncology.
Ultimately, findings from this study will improve our understanding of how digital measures can be combined with more established measures to contribute to holistic measurement of physical function in oncology. Stay tuned for additional results from the study, as well as updates on VivoSense’s efforts to advance the use of digital measures in oncology.